Derivation of Dopaminergic Neurons from Human Pluripotent Stem Cells Using a Defined System and/or Small Molecules

2016 ◽  
pp. 203-217
Author(s):  
Atossa Shaltouki
2019 ◽  
Vol 5 (9) ◽  
pp. FSO418 ◽  
Author(s):  
Mariacruz L Díaz

Parkinson's disease is one of the most insidious neurodegenerative diseases in developed countries. Today, human pluripotent stem cells are produced from embryonic or adult cells, multiplied, differentiated into neural cell lines and ultimately transplanted into disease animal models or patients. Nowadays, DOPAminergic neurons derived from human pluripotent stem cells and human parthenogenetic cells are being clinically tested in China and Australia, respectively. More importantly, good manufacturing practices have been developed and the neurons obtained have been successfully tested in nonhuman primates by teams in Europe, USA and Japan. However, there is a need for translational clinical studies with small molecules tested in vitro, as well as testing of the the efficacy of additional therapies.


2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Xiaojie Ma ◽  
Xi Chen ◽  
Yan Jin ◽  
Wenyan Ge ◽  
Weiyun Wang ◽  
...  

2020 ◽  
Author(s):  
Yuqian Jiang ◽  
Chuanxin Chen ◽  
Lauren N. Randolph ◽  
Songtao Ye ◽  
Xin Zhang ◽  
...  

2012 ◽  
Vol 3 (4) ◽  
Author(s):  
Agnete Kirkeby ◽  
Malin Parmar

AbstractThe challenge with controlling the differentiation of human pluripotent cells to generate functional dopaminergic neurons for the treatment of Parkinson’s disease has undergone significant progress in recent years. Here, we summarize the differences between newer and older protocols for generating midbrain dopaminergic neurons from human pluripotent stem cells, and we highlight the importance of following developmental pathways during differentiation. The field has now developed to a point where it is timely to take human pluripotent stem cells one step closer to clinical use, and cell criteria to be fulfilled for such developments are outlined in this review.


2019 ◽  
Author(s):  
Nobuyuki Eura ◽  
Takeshi K. Matsui ◽  
Joachim Luginbühl ◽  
Masaya Matsubayashi ◽  
Hitoki Nanaura ◽  
...  

SummaryThe brainstem controls heartbeat, blood pressure and respiration, which are life-sustaining functions, therefore, disorders of the brainstem can be lethal. Brain organoids derived from human pluripotent stem cells recapitulate the course of human brain development and are expected to be useful for medical research on central nervous system disorders. However, existing organoid models have limitations, hampering the elucidation of diseases affecting specific components of the brain. Here, we developed a method to generate human brainstem organoids (hBSOs), containing neural crest stem cells as well as midbrain/hindbrain progenitors, noradrenergic and cholinergic neurons, and dopaminergic neurons, demonstrated by specific electrophysiological signatures. Single-cell RNA sequence analysis, together with proteomics and electrophysiology, revealed that the cellular population in these organoids was similar to that of the human brainstem and neural crest, which raises the possibility of making use of hBSOs in grafting for transplantation, efficient drug screenings and modeling the neural crest diseases.


2021 ◽  
Author(s):  
Tingcai Pan ◽  
Ning Wang ◽  
Jiaye Zhang ◽  
Fan Yang ◽  
Yan Chen ◽  
...  

Abstract Background: Various methods have been developed to generate hepatic cells from human pluripotent stem cells (hPSCs) that rely on the combined use of multiple expensive growth factors, limiting industrial-scale production and widespread applications. Small molecules offer an attractive alternative to growth factors for producing hepatic cells since they are more economical and relatively stable. Methods: We dissect small-molecule combinations and identify the ideal cocktails to achieve an optimally efficient and cost-effective strategy for hepatic cells differentiation, expansion, and maturation.Results: We demonstrated that small-molecule cocktail CIP efficiently induced definitive endoderm (DE) formation via increased endogenous TGF-β/Nodal signaling. Furthermore, we identified that combining Vitamin C, Dihexa, and Forskolin (VDF) could substitute growth factors to induce hepatic specification. The obtained hepatoblasts (HBs) could subsequently expand and mature into functional hepatocyte-like cells (HLCs) by the established chemical formulas. Thus, we established a stepwise strategy with complete small molecules for efficiently producing scalable HBs and functionally matured HLCs. The small-molecule derived HLCs displayed typical functional characteristics as mature hepatocytes in vitro and repopulating injured liver in vivo. Conclusion: Our current small-molecule based hepatic generation protocol presents an efficient and cost-effective platform for the large-scale production of functional human hepatic cells for cell-based therapy and drug discovery using.


2014 ◽  
Vol 3 (8) ◽  
pp. 888-898 ◽  
Author(s):  
Jonathan Sagal ◽  
Xiping Zhan ◽  
Jinchong Xu ◽  
Jessica Tilghman ◽  
Senthilkumar S. Karuppagounder ◽  
...  

2018 ◽  
Vol 101 ◽  
pp. 16-24 ◽  
Author(s):  
Faizal Z. Asumda ◽  
Konstantinos E. Hatzistergos ◽  
Derek M. Dykxhoorn ◽  
Silvia Jakubski ◽  
Jasmine Edwards ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document